7 January 2020
On behalf of the Council of EACTS, the Secretary General has written to the principal investigators of the EXCEL trial to offer assistance to resolve the concerns that have been raised about the trial. EACTS has highlighted the importance of making the individual patient data available for independent analysis. In the interests of patient safety, urgent action is required to re-establish the validity of the EXCEL trial in order to provide safe clinical recommendations.
In December 2019, the EACTS Council withdrew its support for the recommendations on left main coronary artery disease of the 2018 joint ESC-EACTS Myocardial Revascularization Guidelines. We also wrote to the ESC inviting our colleagues to work with us jointly to consider the evidence available and develop updated recommendations as a matter of urgency. We await their response.
See the letter from the Secretary General here.